ANKRD39 pseudogene 1 (ANKRD39P1)

ANKRD39 pseudogene 1 (*ANKRD39P1*) is classified as a processed pseudogene in the human genome, meaning it is derived from the mRNA of the protein-coding Ankyrin repeat domain 39 (ANKRD39) gene but has lost its protein-coding capability due to disruptions or lack of essential sequences such as introns[9][2][13]. Processed pseudogenes arise via retrotransposition and typically do not encode functional proteins, but some can exert regulatory effects at the RNA level through mechanisms such as acting as microRNA sponges or antisense regulators[2][5][10]. There is currently no evidence that ANKRD39P1 functions as a receptor or actionable therapeutic target, nor is it a biomarker or safety concern in clinical practice[3][9]. Key evidence supports that ANKRD39P1 is a processed pseudogene, lacking introns and likely arising via mRNA retrotransposition[9][2][13]. It has no known protein product, with bioinformatic and genetic sources classifying it as noncoding[9]. It is not considered a therapeutic target, playing no established direct or indirect role as a receptor, enzyme, or other targetable protein[3][9]. While pseudogenes can sometimes regulate their parental gene or act as competing endogenous RNAs, this is poorly characterized and not specifically established for ANKRD39P1[2][5][10]. The canonical name is "ANKRD39 pseudogene 1", with "ANKRD39P1" as the abbreviated symbol; there are no prominent alternative aliases beyond minor variants[3][9]. Note: Do not confuse ANKRD39P1 (the pseudogene) with ANKRD39 (the functional protein-coding gene), which belongs to the ankyrin repeat domain protein family and may have context-specific disease associations[1][7].